Wikipedia -WSS

Wikipedia

author：explore 2025-09-07 17:29:39 - browse：3375

Stock exchange — Drew Angerer/Getty Images

Sage Therapeutics said Monday that it may need to reduce costs, including through employee layoffs, following the Food and Drug Administration’s denial of its rapid-acting drug for major depressive disorder.

On Friday, the agency granted market clearance for the drug, called Zurzuvae, to treat women with postpartum depression, a smaller commercial market. Sage failed to convince regulators to also approve the drug for depression, a broader condition.

“We don’t agree with the FDA review,” Sage CEO Barry Greene said during an earnings call, a point he made repeatedly. “We are evaluating the [FDA’s response letter] and as soon as we can provide more clarity, we will, on what the next steps are.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Humans aren't the only ones with an imagination. Rats have it too

WSS

Surge of respiratory disease in China has likely explanation

How neuroscience research could help beat back brain cancer

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Bill would allow buprenorphine prescription for addiction via telehealth

After Sarepta trial failure, Duchenne families brace for more debate

CRISPR pioneers react to Casgevy, first gene

hotspot

Wikipedia

explore

At least 13 dead in Texas as scorching temps continue

Gene therapy’s promise and the high cost of hope

Tori Bowie and the unacceptable rates of Black maternal death

Weight loss drug costs may need more research, senator suggests

New air purifier tech could be key to improving indoor air quality

Medicare must police algorithms in Medicare Advantage, Dems say

Hepatitis C has a cure — but many Americans still lack access to it

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Affirmative action in medical school literally saved lives

Brain injuries and the importance of a second opinion

entertainment

Coloradans with cystic fibrosis could lose access to Trikafta

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Life sciences investors close nearly $6 billion in new funds

Key Senate panel to consider PBM, drug pricing reform package

Poor hospice wound care hurts patients and families

focus

leisure time

hotspot

entertainment